NRx Pharmaceuticals’ (NRXP) Buy Rating Reaffirmed at HC Wainwright

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $45.00 target price on the stock.

Several other research analysts have also issued reports on the company. BTIG Research reaffirmed a “buy” rating and set a $10.00 target price on shares of NRx Pharmaceuticals in a research report on Tuesday, August 18th. D. Boral Capital reissued a “buy” rating and issued a $34.00 price objective on shares of NRx Pharmaceuticals in a research note on Tuesday, May 5th. Wall Street Zen cut shares of NRx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Weiss Ratings restated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research note on Wednesday, August 5th. Finally, Ascendiant Capital Markets lifted their target price on shares of NRx Pharmaceuticals from $48.00 to $49.00 and gave the stock a “buy” rating in a research report on Monday, April 27th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $34.50.

NRx Pharmaceuticals Price Performance

NASDAQ:NRXP traded up $0.10 during mid-day trading on Tuesday, reaching $3.55. The stock had a trading volume of 401,911 shares, compared to its average volume of 1,136,410. The stock has a 50-day simple moving average of $3.74 and a two-hundred day simple moving average of $3.02. NRx Pharmaceuticals has a 12 month low of $1.62 and a 12 month high of $5.05. The stock has a market capitalization of $153.76 million, a PE ratio of -6.45 and a beta of 2.18.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its quarterly earnings results on Monday, August 17th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.33). The company had revenue of $1.10 million for the quarter, compared to the consensus estimate of $1.33 million. Equities analysts expect that NRx Pharmaceuticals will post -0.3 EPS for the current year.

Institutional Investors Weigh In On NRx Pharmaceuticals

Several institutional investors have recently bought and sold shares of the stock. Ethos Financial Group LLC lifted its stake in NRx Pharmaceuticals by 33.6% in the first quarter. Ethos Financial Group LLC now owns 15,900 shares of the company’s stock worth $34,000 after acquiring an additional 4,000 shares during the period. State Street Corp boosted its position in shares of NRx Pharmaceuticals by 14.0% during the fourth quarter. State Street Corp now owns 86,984 shares of the company’s stock valued at $236,000 after purchasing an additional 10,700 shares in the last quarter. Two Sigma Investments LP grew its stake in NRx Pharmaceuticals by 66.4% in the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after purchasing an additional 20,880 shares during the period. Geode Capital Management LLC grew its stake in NRx Pharmaceuticals by 17.8% in the fourth quarter. Geode Capital Management LLC now owns 218,866 shares of the company’s stock worth $593,000 after purchasing an additional 33,004 shares during the period. Finally, Global Retirement Partners LLC bought a new position in NRx Pharmaceuticals in the fourth quarter worth $107,000. 4.27% of the stock is currently owned by hedge funds and other institutional investors.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.